Labcorp Holdings (NYSE:LH), a renowned healthcare diagnostics company, has announced a series of key events and strategical movements. The largest healthcare diagnostic company has declared its
Quarterly Dividend, promising shareholders a sustained stream of returns. The company has also been proactive in expanding its portfolio, recently introducing
FDA-Approved Self-Collection Tests for HPV and STI nationwide. The recent financial reports reflect a strong Q4 Sales, however, criticisms arise about an unclear future trajectory.
M&A moves too were observed with Labcorp acquiring select assets of BioReference Health's Oncology and Clinical Testing Services and Invitae. The company has been performing solidly in the market, with their stock hitting a
52-week high at $248.69. They have also priced their
Senior Notes due 2030, 2032, and 2034 amassing a large fund. Amid all this, Labcorp has been making some executive changes as well with CFO Glenn Eisenberg announcing retirement, and a stock sell-off by EVP Mark Schroeder and CEO Adam Schechter. With a promising future in terms of innovation and returns, a conservative investor might need to review these developments thoroughly before making any decisions.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 08 Dec 2022 08:00:00 GMT to Sat, 12 Apr 2025 08:45:03 GMT -
Rating -6
- Innovation -2
- Information 9
- Rumor -8
